Skip to content
Search

Latest Stories

Modi's generics-only drugs plan worries health experts and Indian pharma sector

India's plan to bring in a law to ensure doctors prescribe medicines only by their generic names risks proliferating the sale of substandard drugs in a country where regulation is already lax, doctors and pharmaceutical executives say.

Prime minister Narendra Modi said last month that the government was looking at such a law to improve affordability of medicines in the country of 1.2 billion people, where the majority live on less than $2 a day.


The government has not given any details or timeframe for the planned legislation but some in the industry fear that hasty execution could harm, not help, public health.

Large drugmakers in India such as Cipla and Sun Pharmaceutical Industries that mostly sell generic drugs under their own brand name, or 'branded generics', compete with much smaller garage manufacturers, many of which operate with scant quality checks.

It is a fiercely competitive, high-volume market, dominated by the big players like Cipla, who employ armies of salesmen to sell their drugs. Some doctors say they tend to prescribe branded generics to patients because they are confident of their quality.

While the government wants to make cheaper non-branded drugs available to consumers, pharmaceutical executives said any law would have to stipulate that the drugs consumers get from pharmacists meet certain quality standards.

"I think the quality aspect is very important for the government to address ... to make sure that all companies in India are on the same quality footing," said Cipla's CEO Umang Vohra.

There is no national data comparing the quality of branded generics, versus unbranded ones. But small studies have shown that unbranded drugs, typically procured by the government for the public health system, have quality issues.

A report by the country's federal auditor in 2012 showed that 31 percent of drugs procured by the government for the Armed Forces Medical Stores were substandard in 2010-11, up from about 15 percent in 2006-07.

Results of the government's largest-ever national survey to test drug quality showed this year that roughly 10 percent of the drugs in the government supply chain were not of standard quality, versus 3 percent of drugs available at pharmacies, which are usually branded generics.

"Generics are fine, but there has to be a proper rigorous mechanism to enforce quality, like the U.S., and unless India evolves on that it will be disastrous," said Nilesh Gupta, managing director of Lupin, India's No. 3 drugmaker by sales.

Substandard medicines range from drugs that don't work at all to those that don't work as expected, thereby contributing to antimicrobial resistance - a major global health problem.

"The idea is very good, but the government needs to ensure the availability of good quality generics," said Vijay Panikar, a Mumbai-based diabetologist.

Indian drugmakers' manufacturing standards, including those of big companies such as Sun Pharma, have been found to have fallen short of international standards in recent years. An industry official said last week that it will be at least five years before Indian manufacturing and data reliability meet the standards of the United States, India's biggest drugs export market.

"It's a work in progress ... I think the bigger companies understand the problem and are working to fix it," said Gupta of Lupin.

Health experts warn of a series of problems with the implementation of a generics-only rule. For example, half the Indian market is made up of combination drugs, and it would be impractical to ask doctors to prescribe a series of chemical names, said S. Srinivasan, a doctor and member of the People's Health Movement, a New Delhi-based NGO.

Doctors opposed to the planned new rule warn it would put too much power in the hands of the chemists.

"Today if I write a generic, the chemist will decide which drug to give, and he will obviously give the one in which he has the biggest margin, without caring about quality,"

More For You

OpenAI Restricts ChatGPT’s Image Feature After Viral Ghibli Trend

Altman addressed the impact of the popular Ghibli-style image trend on OpenAI’s resources

Getty

OpenAI limits ChatGPT’s image generation feature amid viral Ghibli image trend

OpenAI CEO Sam Altman has announced temporary limitations on the company’s image generation feature in response to overwhelming demand driven by a viral trend. On Thursday, Altman addressed the impact of the popular Ghibli-style image trend on OpenAI’s resources, particularly its reliance on GPUs (graphics processing units). Altman revealed that the surge in demand for ChatGPT’s image generation tool has led to significant strain on the company’s infrastructure, prompting the introduction of temporary speed limits for users.

In a post on X (formerly Twitter), Altman shared the company’s response to the unexpected demand, stating, “It’s super fun seeing people love images in ChatGPT, but our GPUs are melting. We are going to temporarily introduce some rate limits while we work on making it more efficient. Hopefully won’t be long! ChatGPT free tier will get 3 generations per day soon.”

Keep ReadingShow less
UK-business-district-Getty
The Canary Wharf business district including global financial institutions in London. (Photo: Getty Images)

Economic growth in 2024 slightly higher than estimated: ONS

THE UK economy grew slightly more than first estimated in 2024, according to official data released on Friday, providing a small boost for the government after it revised down its growth forecast for 2025.

The Office for National Statistics (ONS) said gross domestic product expanded by 1.1 per cent in 2024, up from an initial estimate of 0.9 per cent.

Keep ReadingShow less
Sri Lanka posts five per cent GDP growth as it ends years of economic decline

Sri Lanka's president Anura Kumara Dissanayake

Sri Lanka posts five per cent GDP growth as it ends years of economic decline

CASH-STRAPPED Sri Lanka’s economy grew by five per cent in 2024, marking the first full year of expansion since its unprecedented meltdown in 2022, official data showed last Tuesday (18).

The last quarter of 2024 saw the economy expand by 5.4 per cent, bringing the full calendar year’s GDP growth to five per cent, compared to a contraction of 2.3 per cent in 2023.

Keep ReadingShow less
Donald Trump

Speaking from the Oval Office, Trump said, 'What we’re going to be doing is a 25 per cent tariff on all cars that are not made in the US.'

Getty Images

Trump imposes 25 per cent tariffs on foreign-built cars

US president Donald Trump has announced a 25 per cent tariff on imported cars and auto parts, escalating trade tensions with key partners.

The new duties take effect on 3 April and apply to foreign-made cars and light trucks, with additional levies on key auto parts set to follow within the month.

Keep ReadingShow less
Starmer-Trump-Getty

The UK is negotiating a tech-focused trade deal with the US, which could help avoid direct tariff impacts.

Getty Images

UK economy faces pressure from Trump’s tariff threats

THE UK’s economy faces a major risk from US president Donald Trump’s proposed tariffs, the country’s fiscal watchdog warned on Wednesday, citing slow growth and a high debt burden as key vulnerabilities.

Chancellor Rachel Reeves announced cuts to the welfare budget and other spending reductions to meet a key fiscal target aimed at reassuring investors after the 2022 market turmoil under former prime minister Liz Truss.

Keep ReadingShow less